RxDoctor Payments Data

Steven Heard, MD

Dermatology · Shreveport, LANPI 1194936849

Payments from drug & device makers

$6,051in general payments, 2019–2025

Across 367 payments — averaging $16.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novartis$923
  • Sanofi$859
  • Lilly USA, LLC$356
  • LEO Pharma Inc.$317
  • Johnson & Johnson$308
  • plus $2K from 22 others

What the payments were for

  • Food & beverage$5,80196%
  • Education$2504%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,051 in reported general payments places this provider in the 50th percentile of 189 dermatology providers in Louisiana.

See all dermatology providers in Louisiana

Medicare billing

Part B allowed, 2024
$3,046,590
Medicare patients
2,721
Services billed
18,012

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OpzeluraRuxolitinib Phosphate14$29,344
Clobetasol Propionate139$6,831
Ketoconazole265$3,671
Doxycycline Monohydrate341$2,817
Fluocinonide71$2,813
Clindamycin Phosphate84$2,510
Triamcinolone Acetonide234$1,801
Mupirocin238$1,622
Imiquimod23$1,220
Metronidazole20$1,116
Betamethasone Dipropionate23$992
Desonide20$725
Minocycline Hcl31$703
Hydrocortisone154$577
Tramadol Hcl273$503

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Incyte CorporationOpzelura$160$29,34414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 189 dermatology providers in Louisiana.

Other dermatology in Shreveport

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →